Aqueous Cytokine Levels Associated with Severity of Type 1 Retinopathy of Prematurity and Treatment Response to Ranibizumab

Overview

Journal Graefes Arch Clin Exp Ophthalmol

Specialty Ophthalmology

Date 2018 Jun 28

PMID 29948178

Citations 10

Authors

Jiao Lyu

Qi Zhang

Haiying Jin

Yu Xu

Chunli Chen

Xunda Ji

Xiang Zhang

Yuqing Rao

Peiquan Zhao

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine the aqueous humor levels of cytokines in eyes with type 1 retinopathy of prematurity (ROP) before primary intravitreal injection of ranibizumab (IVR).

Methods: Forty-nine infants with type 1 ROP (56 eyes of 28 infants in the threshold ROP group and 42 eyes of 21 infants in the type 1 pre-threshold ROP group) received primary IVR and 49 aqueous humor samples were obtained preoperatively. Aqueous humor samples from 15 infants (15 eyes) undergoing congenital cataract surgery were used as controls. The concentrations of 27 cytokines were measured by a multiplex bead assay. Infants with persistent, recurrent, or progressive ROP after IVR were retreated.

Results: The preoperative aqueous levels of 16 cytokines were significantly different among type 1 pre-threshold, threshold ROP, and control groups (P < 0.05). The concentrations of vascular endothelial growth factor (VEGF) (P < 0.001), interferon-γ (P < 0.001), interleukin (IL)-10 (P < 0.001), and IL-12 (P < 0.001) were the highest in the threshold ROP group, less in the type 1 pre-threshold ROP group, and the lowest in the control group. Retreatment was given to 55% of infants with ROP within a 48-week follow-up period after primary IVR. Higher VEGF (hazard ratio [HR] = 1.001, P = 0.001) and macrophage inflammatory protein-1β (HR = 1.085, P = 0.022) levels were independently correlated with ROP retreatment.

Conclusions: Higher aqueous levels of VEGF and inflammatory cytokines were associated with more severe type 1 ROP and ROP retreatment after primary IVR.

Citing Articles

Tear fluid cytokine analysis: a non-invasive approach for assessing retinopathy of prematurity severity.

Baba T, Uotani R, Inata K, Sasaki S, Shimizu Y, Miura M Jpn J Ophthalmol. 2024; 68(5):482-489.

PMID: 38985404 DOI: 10.1007/s10384-024-01084-0.

Early detection and correlation of tear fluid inflammatory factors that influence angiogenesis in premature infants with and without retinopathy of prematurity.

Vinekar A, Nair A, Sinha S, Vaidya T, Shetty R, Ghosh A Indian J Ophthalmol. 2023; 71(11):3465-3472.

PMID: 37870008 PMC: 10752326. DOI: 10.4103/IJO.IJO_3407_22.

Association between treatment for retinopathy of prematurity and blood monocyte counts.

Obata S, Matsumoto R, Kakinoki M, Sawada O, Sawada T, Saishin Y Jpn J Ophthalmol. 2023; 67(4):382-386.

PMID: 37140746 DOI: 10.1007/s10384-023-00992-x.

Systemic Cytokines in Retinopathy of Prematurity.

Wu P, Fu Y, Lien R, Chiang M, Lee C, Chen H J Pers Med. 2023; 13(2).

PMID: 36836525 PMC: 9966226. DOI: 10.3390/jpm13020291.

The Relationship between the Aqueous VEGF Level and the Severity of Type 1 Retinopathy of Prematurity.

Liang T, Qian Z, Tao Y, Peng Y, Cui Y, Zhang C J Clin Med. 2022; 11(18).

PMID: 36143009 PMC: 9501342. DOI: 10.3390/jcm11185361.

References

Wallace D, Kraker R, Freedman S, Crouch E, Hutchinson A, Bhatt A . Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA Ophthalmol. 2017; 135(6):654-656. PMC: 5521814. DOI: 10.1001/jamaophthalmol.2017.1055. View

Shiraya T, Kato S, Araki F, Ueta T, Miyaji T, Yamaguchi T . Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema. PLoS One. 2017; 12(3):e0174340. PMC: 5367773. DOI: 10.1371/journal.pone.0174340. View

Yu H, Yuan L, Zou Y, Peng L, Wang Y, Li T . Serum concentrations of cytokines in infants with retinopathy of prematurity. APMIS. 2014; 122(9):818-23. DOI: 10.1111/apm.12223. View

Behzadi P, Behzadi E, Ranjbar R . IL-12 Family Cytokines: General Characteristics, Pathogenic Microorganisms, Receptors, and Signalling Pathways. Acta Microbiol Immunol Hung. 2016; 63(1):1-25. DOI: 10.1556/030.63.2016.1.1. View

. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003; 121(12):1684-94. DOI: 10.1001/archopht.121.12.1684. View

Ma J, Mehta M, Lam G, Cyr D, Ng T, Hirose T . Influence of subretinal fluid in advanced stage retinopathy of prematurity on proangiogenic response and cell proliferation. Mol Vis. 2014; 20:881-93. PMC: 4067231. View

Velez-Montoya R, Clapp C, Rivera J, Garcia-Aguirre G, Morales-Canton V, Fromow-Guerra J . Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity. Clin Ophthalmol. 2010; 4:947-53. PMC: 2938272. DOI: 10.2147/opth.s11650. View

. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005; 123(7):991-9. DOI: 10.1001/archopht.123.7.991. View

Appelberg R . Macrophage inflammatory proteins MIP-1 and MIP-2 are involved in T cell-mediated neutrophil recruitment. J Leukoc Biol. 1992; 52(3):303-6. DOI: 10.1002/jlb.52.3.303. View

10.

Tasman W . Multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol. 1988; 106(4):463-4. DOI: 10.1001/archopht.1988.01060130509025. View

11.

Ozaki H, Okamoto N, Ortega S, Chang M, Ozaki K, Sadda S . Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. Am J Pathol. 1998; 153(3):757-65. PMC: 1853023. DOI: 10.1016/S0002-9440(10)65619-2. View

12.

Blencowe H, Lawn J, Vazquez T, Fielder A, Gilbert C . Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013; 74 Suppl 1:35-49. PMC: 3873709. DOI: 10.1038/pr.2013.205. View

13.

Castellanos M, Schwartz S, Garcia-Aguirre G, Quiroz-Mercado H . Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol. 2012; 97(7):816-9. DOI: 10.1136/bjophthalmol-2012-302276. View

14.

Chen S, Lian I, Hwang Y, Chen Y, Chang Y, Lee K . Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina. 2014; 35(4):667-74. DOI: 10.1097/IAE.0000000000000380. View

15.

Kong L, Demny A, Sajjad A, Bhatt A, Devaraj S . Assessment of Plasma Cytokine Profile Changes in Bevacizumab-Treated Retinopathy of Prematurity Infants. Invest Ophthalmol Vis Sci. 2016; 57(4):1649-54. DOI: 10.1167/iovs.15-18528. View

16.

Lorenz B, Stieger K, Jager M, Mais C, Stieger S, Andrassi-Darida M . RETINAL VASCULAR DEVELOPMENT WITH 0.312 MG INTRAVITREAL BEVACIZUMAB TO TREAT SEVERE POSTERIOR RETINOPATHY OF PREMATURITY: A Longitudinal Fluorescein Angiographic Study. Retina. 2016; 37(1):97-111. DOI: 10.1097/IAE.0000000000001126. View

17.

Sato T, Kusaka S, Shimojo H, Fujikado T . Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology. 2009; 116(11):2165-9. DOI: 10.1016/j.ophtha.2009.04.026. View

18.

Feng J, Qian J, Jiang Y, Zhao M, Liang J, Yin H . Efficacy of Primary Intravitreal Ranibizumab for Retinopathy of Prematurity in China. Ophthalmology. 2016; 124(3):408-409. DOI: 10.1016/j.ophtha.2016.10.032. View

19.

Sood B, Madan A, Saha S, Schendel D, Thorsen P, Skogstrand K . Perinatal systemic inflammatory response syndrome and retinopathy of prematurity. Pediatr Res. 2009; 67(4):394-400. PMC: 2873779. DOI: 10.1203/PDR.0b013e3181d01a36. View

20.

Johnsen-Soriano S, Sancho-Tello M, Arnal E, Navea A, Cervera E, Bosch-Morell F . IL-2 and IFN-gamma in the retina of diabetic rats. Graefes Arch Clin Exp Ophthalmol. 2010; 248(7):985-90. DOI: 10.1007/s00417-009-1289-x. View